dysfunction than the general population. The incidence of cognitive impairment among epileptics is 40%. [1] Their worries include learning disabilities, academic difficulties, poor attention and concentration, and impoverished memory. [2, 3] In a survey by the International Bureau of Epilepsy, 44% of patients with epilepsy complained of difficulty in learning, and 45% of slowness in thinking. [4] It has also been demonstrated that cognitive function is a significant predictor of self-evaluation of the quality of life among adults with epilepsy. [5] Cognitive disturbances in epilepsy are multifactorial in origin including underlying neuropathology, anti-epileptic drugs (AEDs) and psychosocial issues of the patient due to the disease. [6] The incidence of AED-induced cognitive dysfunction is about 28%. [7] Older AEDs have higher cognitive disturbances than newer AEDs. [8, 9] There is no specific treatment available for the cognitive impairment of these patients. [10] Excitotoxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy. [11, 12] Alteration of this excitotoxic pathway can be a novel, potentially safer and more effective, approach to the treatment of memory loss. [13, 14] Memantine is a noncompetitive antagonist of the NMDA-type glutamate receptor. It interacts with the Mg 2+ binding site of the channel to prevent excessive activation while sparing normal function. [15] Memantine significantly reduces the rate of clinical deterioration in patients with moderate to severe Alzheimer's dementia by reducing excitotoxicity and preventing cell damage. [16] This drug exerts its therapeutic effect in various conditions mainly by blocking glutamate excitotoxicity. It also has antioxidant property and increases production of brain-derived neurotropic factor (BDNF). [13, 17] Memantine is approved drug by Food and Drug Administration (2004) for the treatment of cognitive impairment in Alzheimer's dementia. This drug is also commonly used to treat other neurodegenerative dementias.
Memantine available as memantine hydrochloride is administered orally at an initial dose of 5 mg once daily. The maximum tolerable dose is 20 mg. [14] Memantine is well tolerated and safe as shown in all reported trials with hardly few side effects a headache or dizziness, but are usually mild and reversible. [12, 18, 19] Hence, we aimed to evaluate primarily the efficacy of memantine on improving cognition and memory in epileptic patients taking AEDs, with mild to moderate cognitive and memory impairment.
Methods

Study design and eligibility criteria
This study was a randomized, double-blind, placebo-controlled, parallel design trial done for 16 weeks. Epilepsy patients taking AEDs with subjective memory complaints visiting Neurology Outpatient Department of SRM. Medical College Hospitals and Research Centre, Potheri, Kattankulathur, Kancheepuram, Tamil Nadu, India were recruited for the study. Patients on AEDs for more than 6 months with mild to moderate cognitive impairment of age group between 18 and 55 years with seizure frequency of <4 per month were included in the study. The exclusion criteria were patients with the progressive neurologic disease, psychiatric disorders, mental retardation, severe medical illnesses including renal insufficiency, pregnant or lactating women, patients who are not willing to give consent. Patients in inter-ictal period (2 weeks) and patients with more than four seizure attacks per month also were excluded participation as they might have severe memory impairment. Recruitment of the patients began in March 2013. Patients were assessed for intelligent quotient (IQ) testing by clinical psychologist using Stanford-Binet Intelligence Scale. After verifying eligibility for normal IQ and signing the consent for participation, patients were included in the study.
Trial procedures
Randomization and blinding
We used sequentially numbered, opaque, sealed envelope pattern for allocation concealment. [20] The random code was generated before commencement of the study. After a screening period of up to 4 weeks, eligible participants were randomly assigned to one of the two groups, Group 1 memantine and Group 2 placebo. Randomization was done by random number generator software. Patients, investigators and outcome assessors were blinded. The identity of the treatment was concealed by the use of study drugs that were identical in appearance, packaging, labelling and in the schedule of administration. [20] Evaluation of patients and treatment Participants underwent a screening neurological history and examination; documentation of a seizure diary and case record forms were maintained for each patient. The baseline assessment of cognition was done using Folstein mini-mental state examination (MMSE) scale, and memory was done using Weshler Memory Scale (WMS) for adults, quality of life in epilepsy (QOLIE) was by QOLIE-10-P questionnaire. [21, 22] Interventional drug memantine hydrochloride tablet 5 mg, 10 mg was obtained from Sun Pharma Pvt. Ltd. Treatment and placebo drugs were concealed as prelabelled kits.
Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 8 weeks and dose is titrated to 10 mg once daily orally cautiously for the remaining 8 weeks. Duration of intervention was 4 months. Placebo was given once daily orally for 16 weeks. Patients were instructed to take the study medication at the same time every day. Duration of intervention was 4 months. Follow-up evaluation for cognitive and memory assessment using MMSE and WMS, questionnaire were done at the end of 4 th , 8 th , 12 th and 16 th week respectively and quality of life using QOLIE-10 was also assessed at the same time. Patients were asked to bring the dispensed drug pack at each visit to check for drug accountability record. Patients were asked for any adverse reactions during each visit, the data was recorded, and seizure diary was also monitored.
Statistical analysis
We expressed descriptive data as mean ± standard deviation. Continuous data post-treatment changes compared to baseline by paired Student's t-test and between groups by unpaired t-test. We used Wilcoxon signed ranks test to compare the WMS subset assessment between baseline and their respective follow-up weeks. Mann-Whitney U-test was the statistical method used to compare the mean WMS subset assessment scores between the groups at their respective follow-up weeks. Pearson Chi-square continuity ratio and Fisher's exact test were used for WMS and MMSE scale interpretation. Levene's test for equality of variances was used for quality of life assessment and significance was given by t-test for equality of means between baseline and their respective follow-up weeks. We used Statistical Package for Social Sciences (SPSS Statistics for Windows Version 17.0. Chicago: SPSS Inc.) P ≤ 0.05 was considered statistically significant.
Results
We screened 89 epileptic patients with the subjective memory complaints for eligibility to enrol in the study. A total of 59 patients were included in the study. The reasons for exclusion of other screened cases were severity of seizure, age > 55 years, severe memory impairment, alcohol withdrawal seizures and not willing for consent. Between April 2013 and May 2013, the eligible patients were enrolled, allocated into two groups, randomly assigned to one of two groups, which was shown in Figure 1 .
Group 1 with 29 patients received memantine and Group 2 with 30 patients received placebo treatment. Out of 29, three patients of memantine group and out of 30, one patient of placebo group lost follow-up. Fifty-five patients were taken for follow-up analysis, with 26 patients in memantine group, and 29 patients in placebo group.
The demographic data were discussed in Table 1 . Baseline characteristics were similar in all the treatment groups.
MMSE score increased in memantine group, baseline (P = 0.765) to 16 th week (P = 0.000***) (CI = 95%) in comparison with the placebo as shown in Figure 2a .
WMS score increased in memantine group, improved significantly after 8 weeks (P = 0.002**) compared with baseline (P = 0.873) and highly significant at the end of 16 th week (P = 0.000***) (CI = 95%) in comparison with the placebo as shown in Figure 2b . The within-group comparison of memantine for 5 mg and 10 mg, 10 mg dose titration showed a highly significant improvement in MMSE and WMS score (P = 0.000***) at the end of 16 th week of treatment when compared with 5 mg dose of memantine (P ≤ 0.05*) at the end of 8 th week.
Memantine group showed improved logical memory from baseline (P = 0.247), which is statistically significant at the 8 th week follow-up (P = 0.002**), and highly significant at the 12 th (P = 0.000***) and 16 th follow-up week (P = 0.000***) in comparison with the placebo [ Figure 3a ]. Memory span is increased in memantine group from baseline (P = 0.661) which is statistically significant at the 8 th week follow-up (P = 0.003**) week, and highly significant at the 12 th and 16 th follow-up week (P = 0.000***) in comparison with the placebo [ Figure 3b ]. There is increase visual reproduction memory in memantine group, which is statistically significant at the 8 th week follow-up (P = 0.008**), and highly significant at the 12 th and 16 th follow-up week (P = 0.000***) as shown in Figure 3c , in comparison with the placebo. In Memantine group, associate learning is improved, which is statistically significant at the 12 th week follow up (*P < 0.05), and highly significant at 16 th week follow up (** P < 0.001) as shown in Figure 3d in comparison with the placebo.
Memantine treatment showed statistically significant improvement in memory at the end of 16 th week (P = 0.000***) in comparison with the placebo which is shown in Table 2a .
The self-rated quality of life questionnaire showed statistically (P = 0.000***) significant improvement in memory and quality of life in patients receiving memantine treatment at the end of the study as given in Table 2b . Table 3 gives the list of adverse drug events noted during the study period.
Discussion
Cognitive and memory impairment are very common in epileptic patients due to multifactorial etiology. [23, 24] AED treatment itself can cause cognitive dysfunction as side effect. [25, 26] To our knowledge, this trial is the first clinical study to evaluate the effect of memantine on improving cognition and memory in epileptic patients.
In our study, there is a significant improvement in cognition in memantine group assessed by MMSE score compared with the placebo. This effect started at the 4 th week of memantine therapy and highly significant improvement in cognitive score was seen at the 12 th and 16 th week of follow-up (P = 0.000), which corresponds to 10 mg once daily dosage of memantine. Our study also showed statistically significant improvement in memory assessed by WMS in memantine group compared with the placebo. This significant effect was observed from the 9 th week of memantine therapy and highly significant improvement was seen at the 16 th week of follow-up (P = 0.000).
The molecular mechanism behind cognitive and memory impairment in epileptic patients receiving AEDs is due to excitotoxic damage caused to the brain by the excitatory neurotransmitter glutamate through NMDA receptor. This glutamate excess affects long term potentiation and learning under pathological conditions which lead to neuronal cell death and free radical formation. [12, 27] The interventional drug in our study, memantine is an NMDA receptor antagonist (noncompetitive). It can prevent the excitotoxic damage to the brain by blocking the NMDA receptor channel and by preventing glutamate action, which contribute to cognitive and memory improvement as shown by our study. In addition, memantine reduces oxidative stress and increases the level of BDNF, which in turn would add to memory improvement. The transient blockade of activated NMDA receptors by low-affinity agents, inhibits their pathological functions only, leaving physiological functions unaltered. [14] Memantine is a fast-binding antagonist which binds to the channel in a pseudo-first order manner. It also dissociates from the receptor quickly and in a concentration independent manner which allows the binding of memantine without affecting its removal from the site of action and increased potency with fewer side effects. [28] In comparison with other antagonists (dextromethorphan, ketamine, amantadine), memantine is fast acting and has less effect on physiologic mechanisms. [29] Subset assessment of memory showed improvement in mental control in memantine group (P < 0.05) at 10 mg dose. Logical memory showed statistically significant improvement in the memantine group (P = 0.000) at 12 th and 16 th week which corresponds to the dose of 10 mg once daily. Memory span subset of WMS also showed highly significant improvement in the memantine group at the 12 th and 16 th week in comparison with the placebo. Visual reproduction subset also showed highly significant improvement in the memantine group at the 12 th and 16 th week. Associate learning subset of memantine group showed statistically significant improvement 16 th follow-up week in comparison with the placebo.
Based on our results, there is significant improvement in cognitive and memory dysfunction for epileptic patients at 10 mg once daily oral dose.
As the efficacy of memantine is investigated in epilepsy, which is one of a critical disease, we cautiously started with an initial therapeutic dose of 5 mg for the first 8 weeks followed by 10 mg for the next 8 weeks.
Memantine also improved the self-reported memory function and quality of life in epileptic patients as assessed by QOLIE-10-P questionnaire with minimal side effects. In our study, the memantine group had low seizure frequency in comparison with baseline as observed from the seizure dairy of patients. The seizure reducing ability of memantine can be evaluated in detail for control of seizures in future.
This study also has some limitations. The study period was relatively short. Long-term assessment for the efficacy and safety of memantine can be investigated. We recruited adult patients of age between 18 and 55 years; however the incidence of cognitive impairment in adolescent age group epileptic patients is around 50%, which would certainly impair the cognitive and academic performances of these patients. The possible effect of memantine to improve memory in children and adolescent age group epileptic patients can also be done.
Conclusion
From this randomized, double-blind, placebo-controlled, parallel design study to evaluate the efficacy of memantine for mild to moderate cognitive impairment in epileptic patients, we conclude that memantine 10 mg oral, once daily significantly improves mild to moderate cognitive and memory impairment in epileptic patients receiving AEDs when compared with placebo group. Self-reported memory and quality of life significantly improved with 10 mg once-daily memantine at the end of 16 th week of treatment. 
